NCT05904054View on ClinicalTrials.gov

Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV)

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

May 31, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

SARS-CoV-2 DNA Vaccine (ICCOV)

The SARS-CoV-2 DNA Vaccine (ICCOV) was developed by Immuno Cure Holding (HK) Limited.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The unit dose strength is 1 mg/0.5 mL and the dose volume is 1.0 mL/dose.

Trial Locations (1)

Unknown

Gleneagles Hospital Hong Kong, Wong Chuk Hang

All Listed Sponsors
collaborator

The University of Hong Kong

OTHER

lead

Immuno Cure 3 Limited

INDUSTRY

NCT05904054 - Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV) | Biotech Hunter | Biotech Hunter